General
FDA approves new indication for empagliflozin
 

FDA approves new indication for empagliflozin

Shared by:

 
The US Food and Drug Administration (FDA) has approved empagliflozin for adult patients with type 2 diabetes (T2D) and coexisting cardiovascular disease (CVD), making it the first diabetes drug approved to reduce the risk of cardiovascular death in this population.
 
specialty.mims.com
 
15 Dec 2016 - General